What question did this study set out to answer?

To evaluate serum Galectin-3 concentrations across chronic kidney disease stages and investigate their association with microinflammation and cardiac dysfunction in maintenance hemodialysis patients.

August 15, 2026Kidney and DialysisOpen Access

Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients

View Full Paper

Ask AI

Bookmark

Authors

HDHao Thi Minh DinhHue University NTNgoc That TonHue Central Hospital TVTam VoSewanee: The University of the South

Discussion

Member takes

Implication

Cross-sectional study finds serum galectin-3 rises across kidney disease stages and links to inflammation, suggesting limited diagnostic utility for cardiac dysfunction in hemodialysis.

Key Points

To evaluate serum Galectin-3 concentrations across chronic kidney disease stages and investigate their association with microinflammation and cardiac dysfunction in maintenance hemodialysis patients.
Conducted a cross-sectional study of 206 patients across CKD stages 3–5 non-dialysis, maintenance hemodialysis, and post-kidney transplantation, alongside 70 healthy controls.
Measured serum Galectin-3 using a Chemiluminescent Microparticle Immunoassay and evaluated correlations with C-reactive protein, troponin T, and echocardiographic ejection fraction.
Median Galectin-3 concentrations rose progressively across CKD stages (stage 3: 29.50 ng/mL; stage 4: 39.85 ng/mL; stage 5 non-dialysis: 52.70 ng/mL; maintenance hemodialysis: 65.15 ng/mL) and dropped after transplantation (19.45 ng/mL).
Hemodialysis patients with high Galectin-3 (>65.15 ng/mL) had higher CRP levels than those with low levels (2.39 vs. 1.22 mg/L, p = 0.013), and Galectin-3 correlated with troponin T (r = 0.266, p = 0.037), though this lost significance after multivariable adjustment (p = 0.057).
Galectin-3 did not significantly discriminate left ventricular systolic dysfunction (EF < 50%), yielding an AUC of 0.557 (95% CI: 0.401–0.714) and non-significant discrimination at a cut-off of ≥52.85 ng/mL (sensitivity: 86.7%, specificity: 31.9%, p = 0.506).

Cite This Study

Dinh et al. (2026) studied this question.

synapsesocial.com/papers/6a8037d975c2e31742c86ebd https://doi.org/10.3390/kidneydial6030056

View Full Paper

Ask AI

Bookmark

Implication

Cross-sectional study finds serum galectin-3 rises across kidney disease stages and links to inflammation, suggesting limited diagnostic utility for cardiac dysfunction in hemodialysis.

Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider